First National Daily eMedical Newspaper of India
Nobody Reports News Better Than Us  
Editorial (Dr K K Aggarwal)                                                                                                    (Dr RN Tandon)
To Read the full story on, or download our Android app or iOS app
13th January 2017
IMA Advisory: Alert on use of sodium valproate in pregnant women
These five congenital anomalies could have been saved
Dear Colleague
Sodium valproate in pregnant women is widely prescribed by the clinicians of many hospitals, which is a matter of great concern as this drug belongs to pregnancy category D (There is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience or studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.).
A total of 5 individual case safety reports have been reported in the NCC-PvPI database. These children born were identified to have congenital anomaly after receiving sodium valproate by their mothers during pregnancy. 
Kindly DO NOT PRESCRIBE sodium valproate in pregnancy.
Report immediately at 9717776514 if such issues are identified with the use of sodium valproate for further actions.
(Contributions from Dr V Kalaiselvan, Principal Scientific Officer, NCC-PvPI, Indian Pharmacopoeia Commission)
Dr KK Aggarwal
National President IMA and HCFI
To Read More or Comment, Click Here
Top News
Practice Updates
eMedi Humor
Medicolegal Corner
eMedi Quiz
1. Obesity.
2. Family history.
3. Use of hormone replacement therapy
4. Early menopause.
Lifestyle Updates
Inspirational Story 1: The Three Dolls
Inspirational Story 2: Knowing Yourself
Press Release
Importance of pharmacovigilance and reporting of adverse drug events

IMA urges its 2.8-lakh members to report each and every adverse drug reaction to reduce incidence of preventable deaths

New Delhi, January 12 2016: Recently, the pace with which newer drugs are being introduced in India and worldwide has been increasingly steadily. These drugs come from a tightly regulated pipeline of clinical trials and safety evaluations. The drug, once in the market can then be subjected to a final round of scrutiny by monitoring adverse drug reactions (ADR). Reporting of ADR can facilitate early detection of signals of new, rare and serious ADRs. It also can potentially provide information about the safety and efficacy of the drug in the long run and ultimately safeguards the patients.  
To Read More or Comment, Click Here
Pedicon 2017